Background Current microbiome-based therapeutics face two prominent issues: the limited clinical efficacy of probiotics and the significant variability in the efficacy of microbiota transplantation ...

It is reported that up to 10–25% of all diagnoses of inflammatory bowel disease (IBD) occur in those aged less than 18 years.1 The long-term impact of disease for those likely to live 70+ years with ...

A 36-year-old man presented with abdominal pain lasting 5 months and muco-bloody stools for 1 month. Subsequently, he progressed to incomplete intestinal obstruction (defaecation difficulty and ...

1 Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan 2 Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan ...

Objective The absent in melanoma 2 (AIM2) cytosolic pattern recognition receptor and DNA sensor promotes the pathogenesis of autoimmune and chronic inflammatory diseases via caspase-1-containing ...

Objectives National guidelines for the management of irritable bowel syndrome (IBS) recommend that psychological therapies should be considered, but their relative efficacy is unknown, because there ...

Background Non-invasive biomarkers with biological rationale are needed for identifying patients with progressive metabolic dysfunction-associated steatohepatitis (MASH). Objective To test the ...

Objective Anti-NKG2D (NNC0142-0002) is an antagonising human immunoglobulin G4 monoclonal antibody that binds to natural killer group 2 member D (NKG2D) receptors, which are expressed by T cells and ...

7 Department of Paediatrics, St George's Hospital, London, UK 8 Department of Gastroenterology, St. Mary's Hospital, London, UK 9 Department Gastroenterology, University Hospital of North Tees, UK The ...

Background and aims A general dysbiosis of the intestinal microbiota has been established in patients with Crohn's disease (CD), but a systematic characterisation of this dysbiosis is lacking.

Refractory coeliac disease (RCD) is defined by persistent or recurrent malabsorptive symptoms and villous atrophy despite strict adherence to a gluten-free diet (GFD) for at least 6–12 months in the ...

3 Department of Clinical and Experimental Medicine, Division of Pediatrics, Linköping University, Linköping, Sweden 4 Department of Clinical and Experimental Medicine, Division of Inflammation ...